Medindia

X

Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update

Wednesday, May 11, 2011 General News J E 4
Advertisement

Neuralstem, Inc.

Statements of Operations

Three Months

Ended March 31,

2011

2010

Revenues

$          -

$         -

Operating expenses:

Research and development costs

1,738,728

1,899,963

General and administrative expenses

1,772,482

1,687,835

Depreciation and amortization

25,293

29,063

Total operating expenses

3,536,503

3,616,861

Operating loss

(3,536,503)

(3,616,861)

Nonoperating income (expense):

Litigation settlement

250,000

-

Interest income

22,892

5,811

Interest expense

-

(659)

Warrant issuance and modification expense

-

(1,906,800)

Gain (loss) from change in fair value adjustment of warrant obligations

161,809

(1,248,452)

Total nonoperating income (expense)

434,701

(3,150,100)

Net loss attributable to common shareholders

$   (3,101,802)

$  (6,766,961)

Net loss per share - basic and diluted

$        (0.07)

$       (0.18)

Weighted average common shares outstanding - basic and diluted

47,692,878

38,539,226

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
DuPage Medical Group, Edward Hospital Announce Gro...
S
Invest in Youth, Women, Reproductive Health to Red...